Innovation Drives Market Gains in Biopharmaceuticals
This article was published in Genetic Engineering News in the section "Wall Street Biobeat" on April 1, 2011. Monoclonal antibody therapies remain the dominant technology with immunotherapy and stem cell therapies on the horizon. GEN | Articles: Innovations Continue to Drive Market Gains...
Decent Follow Through From Yesterday’s Biotech Rally
Biopharmaceutical stocks caught bids today (in a weak technology market) after yesterday's M&A spiked rally. Large cap leaders in the NASDAQ-100 were up: Biogen(BIIB) up 1.63%, Celgene (CELG) up 1.6% and Gilead (GILD) up 0.68%. Major ETF's-IBB FBT XBI- also gained about 0.5%.Amgen(AMGN) was...
Caution on Optimer (OPTR) Down 3% in Strong Biotech Market-update April 1 OPTR up 11%
Optimer soars 11% to $13.13 on presentation of Shea Data and preliminary FDA review: Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients - Yahoo! Finance Optimer Rises After FDA Staff Says...
Biotech Sector Soars On Valeant (VRX) Bid For Cephalon (CEPH)
Biopharmaceutical Stocks Ignited By M&A Potential M&A has been a key driver for investing in biotech stocks as need for product pipeline and technologies grows. The drug development process is slow and synergies can be found faster by buying companies on the open market. New drugs...
Rayno Life Science Portfolio: Cephalon (CEPH) Up 27% After Hours on Valeant (VRX) Hostile Bid- UPDATE
3/30/11 Update CEO Michael Pearson of Canadian based Valeant (VRX) reiterated his determination(live on CNBC this am) for buying Cephalon (CEPH) after being stalled by the Board of CEPH after initial discussions.Mr. Pearson stated he wanted to move quickly and if the deal stalls he would...